Characteristic
All patients (no. of patients = 34)
Male gender 17 (50%)
Median age at study entry, year (range) 10 (3-17%)
Underlying disease*
ALL
19 (56%)
AML
8 (24%)
Other
9 (26%)
Stem-cell transplantation
Overall
13 (38%)
Allogeneic
13 (38%)
Autologous
0
BMT <6 months before infection
10 (29%)
Disease status
Remission
23 (68%)
Non-complete remission
11 (32%)
Severe neutropenia (ANC<500/mm3)
31 (91)
Mean duration of neutropenia, days ± SD
17 ± 14
Risk classification for fungal infection
Standard risk
12 (35%)
High risk
22 (65%)
Post-BMT
13 (38%)
Relapsing leukemia
11 (32%)
AML
8 (24%)
High-risk ALL
6 (18%)
Surgical treatment
No. of ESS, mean (range)
3.2 (1-11)
Multiple procedures
24 (71%)
Extrasinus extension
11 (33%)
PCR detection 22 (65%)
Fungal pathogen
Aspergillus
20 (59%)
Mucormycosis
12 (35%)
Other
20 (59%)
Systemic antifungal therapy
Amphotericin B
9 (26%)
Ambisome
13 (38%)
Voriconazole
11 (32%)
Mortality
Overall
13 (38%)
Dead of infection
9 (26%)